Government Patent Use to Promote Public Health in the United States: Overcoming Nonpatent Exclusivities

Am J Public Health. 2022 Aug;112(8):1110-1114. doi: 10.2105/AJPH.2022.306888. Epub 2022 Jun 16.

Authors

Rebecca E Wolitz¹, Aaron S Kesselheim¹, Jonathan J Darrow¹

Affiliation

¹ Rebecca E. Wolitz is with the Moritz College of Law, The Ohio State University, Columbus. Jonathan J. Darrow and Aaron S. Kesselheim are with the Program on Regulation, Therapeutics, and Law, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA. Jonathan J. Darrow is also with the Department of Law & Taxation, Bentley University, Waltham, MA.

PMID: 35709409
PMCID: PMC9342817 (available on 2024-08-01)
DOI: 10.2105/AJPH.2022.306888

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural

MeSH terms

Drug Industry*
Federal Government
Government
Humans
Public Health*
United States
United States Food and Drug Administration